Valuation
- Market cap
- 139,148,000
- Revenue TTM
- $0
- Net income TTM
- $-24,200,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 1,101,700
- Avg volume
- 1,544,774
- Day's range
- $1.11 – $1.16
- Shares out
- 118,930,000
- Stochastic %K
- 33%
- Beta
- 0.88
- Analysts
- Strong Sell
- Price target
- $7.99
Company profile
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of rec...
Show more
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol for the treatment of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- Phone
- 289 910 0850
- Website
- https://www.cardiolrx.com
- Address
- 2265 Upper Middle Road East, Suite 602, Oakville, Canada
Latest news
No headlines yet.
